Biological impact of freezing Plk1 in its inactive conformation in cancer cells

Cell Cycle

Volumn 9, Issue 4, 2010, Pages 761-774

  Keppner, Sarah ^a   Proschak, Ewgenij ^a   Kaufmann, Manfred ^a   Strebhardt, Klaus ^a   Schneider, Gisbert ^a   Spänkuch, Birgit ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Inactive conformation; Kinase inhibitor; Polo like kinase 1 (Plk1)

Indexed keywords

AURORA A KINASE; CASPASE; PHOSPHOTRANSFERASE; POLO LIKE KINASE 1; POLO LIKE KINASE 2; POLO LIKE KINASE 3; PROTEIN SERINE THREONINE KINASE INHIBITOR; SBE 13; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZYLAMINE DERIVATIVE; CASPASE 9; CELL CYCLE PROTEIN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIDINE DERIVATIVE; SBE13 COMPOUND;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MITOSIS; PROTEIN CONFORMATION; WESTERN BLOTTING; CELL DIVISION; DRUG ANTAGONISM; HELA CELL; METABOLISM; TIME; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZYLAMINES; CASPASE 9; CELL CYCLE PROTEINS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE; HELA CELLS; HUMANS; MITOSIS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PYRIDINES; TIME FACTORS;

EID: 77953170553     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.9.4.10644     Document Type: Article

References (36)

1. Glover DM, Hagan IM, Tavares AA. Polo-like kinases: a team that plays throughout mitosis. Genes Dev 1998; 12:2-4.
2. Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA 1994; 91:1736-40.
3. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6:321-30.
4. Schmit TL, Zhong W, Nihal M, Ahmad N. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009; 8:2697-702.
5. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005; 24:267-76.
6. Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature 2001; 410:215-20.
7. Yuan J, Eckerdt F, Bereiter-Hahn J, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene 2002; 21:8282-92.
8. Toyoshima-Morimoto F, Taniguchi E, Nishida E. Plk1 promotes nuclear translocation of human Cdc25C during prophase. EMBO Rep 2002; 3:341-8.
9. Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ 2000; 11:615-23.
10. van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle 2006; 5:853-64.
11. Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100:5789-94.
12. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K, et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115:978-85.
13. Ahmad N. Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer. FASEB J 2004; 18:5-7.
14. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996; 135:1701-13.
15. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA Silencing of Polo-Like Kinase-1 (PLK1) on Apoptosis and Spindle Formation in Human Cancer Cells. J Natl Cancer Inst 2002; 94:1863-77.
16. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene 2002; 21:3162-71.
17. Spankuch B, Matthess Y, Knecht R, Zimmer B, Kaufmann M, Strebhardt K. Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst 2004; 96:862-72.
18. Liu X, Erikson RL. Polo-like kinase 1 in the life and death of cancer cells. Cell Cycle 2003; 2:424-5.
19. Lenart P, Petronczki M, Steegmaier M, Di FB, Lipp JJ, Hoffmann M, et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007; 17:304-15.
20. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007; 17:316-22.
21. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008; 26:5504-10.
22. Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N, et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 2005; 7:275-86.
23. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, et al. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis. Cancer Res 2009; 69:6969-77.
24. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15:3094-102.
25. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2:358-64. (Pubitemid 43936934)
26. Keppner S, Proschak E, Schneider G, Spankuch B. Identification and Validation of a Potent Type II Inhibitor of Inactive Polo-like Kinase 1. ChemMedChem 2009.
27. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Watanabe N, Hunter T, et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci USA 2004; 101:4419-24. (Pubitemid 38437427)
28. McInnes C, Mazumdar A, Mezna M, Meades C, Midgley C, Scaerou F, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol 2006; 2:608-17. (Pubitemid 44610345)
29. Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 2007; 6:450-9.
30. Sumara I, Gimenez-Abian JF, Gerlich D, Hirota T, Kraft C, de la TC, et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 2004; 14:1712-22. (Pubitemid 39301160)
31. Qin L, Tong T, Song Y, Xue L, Fan F, Zhan Q. Aurora-A interacts with Cyclin B1 and enhances its stability. Cancer Lett 2009; 275:77-85.
32. Sanchez C, Mendoza P, Contreras HR, Vergara J, McCubrey JA, Huidobro C, et al. Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate 2009; 69:1448-59.
33. Grunwald V, DeGraffenried L, Russel D, Friedrichs WE, Ray RB, Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res 2002; 62:6141-5. (Pubitemid 35244463)
34. Kreis NN, Sommer K, Sanhaji M, Kramer A, Matthess Y, Kaufmann M, et al. Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle 2009; 8:460-72.
35. Jang YJ, Lin CY, Ma S, Erikson RL. Functional studies on the role of the C-terminal domain of mammalian polo-like kinase. Proc Natl Acad Sci USA 2002; 99:1984-9. (Pubitemid 36157840)
36. Spankuch B, Heim S, Kurunci-Csacsko E, Lindenau C, Yuan J, Kaufmann M, et al. Downregulation of Polo-like Kinase 1 Elevates Drug Sensitivity of Breast Cancer Cells In vitro and In vivo. Cancer Res 2006; 66:5836-46. (Pubitemid 43927138)